Hypogammaglobulinemia and Risk of Exacerbation and Mortality in Patients with COPD
Open Access
- 1 April 2020
- journal article
- research article
- Published by Taylor & Francis Ltd in International Journal of Chronic Obstructive Pulmonary Disease
- Vol. ume 15, 799-807
- https://doi.org/10.2147/copd.s236656
Abstract
Introduction: Chronic obstructive pulmonary disease (COPD) may, in some patients, be characterized by recurring acute exacerbations. Often these exacerbations are associated with airway infections. As immunoglobulins (Ig) are important parts of the immune defence against airway infections, the aim of this study was to relate the levels of circulating immunoglobulins to clinical features in unselected patients with COPD included in a Norwegian multicenter study. Methods: Clinical and biological data, including circulating levels of immunoglobulins, were assessed in 262 prospectively included patients with COPD GOLD stage II–IV at five hospitals in south-eastern Norway. A revisit was done after one year, and survival was assessed after five years. Clinical features and survival of those with immunoglobulin levels below reference values were compared to those with normal levels. Results: In total, 11.5% of all COPD patients and 18.5% of those with GOLD stage IV had IgG concentrations below reference values. These patients were more likely to use inhaled or oral steroids, had lower BMI, and lower FEV1%. Moreover, they had significantly more COPD-related hospital admissions (2.8 vs 0.6), number of prednisolone courses (3.9 vs 1.2), and antibiotic treatments (3.7 vs 1.5) in the preceding year. Importantly, hypogammaglobulinemia was significantly associated with reduced survival in a log-rank analysis. In multivariate regression analysis, we found that the higher risk for acute exacerbations in these patients was independent of other risk factors and was associated with impaired survival. Conclusion: In conclusion, our study suggests that hypogammaglobulinemia may be involved in poor outcome in COPD and may thus be a feasible therapeutic target for interventional studies in COPD.This publication has 42 references indexed in Scilit:
- Characterisation of exacerbation risk and exacerbator phenotypes in the POET-COPD trialRespiratory Research, 2013
- Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary DiseaseAmerican Journal of Respiratory and Critical Care Medicine, 2013
- Treatment of COPD by clinical phenotypes: putting old evidence into clinical practiceEuropean Respiratory Journal, 2012
- Susceptibility to Exacerbation in Chronic Obstructive Pulmonary DiseaseThe New England Journal of Medicine, 2010
- Structure and function of immunoglobulinsJournal of Allergy and Clinical Immunology, 2010
- Pathophysiology of Exacerbations of Chronic Obstructive Pulmonary DiseaseProceedings of the American Thoracic Society, 2006
- The self‐administered comorbidity questionnaire: A new method to assess comorbidity for clinical and health services researchArthritis Care & Research, 2003
- IgG subclasses in smokers with chronic bronchitis and recurrent exacerbationsThorax, 2001
- Usefulness of the Medical Research Council (MRC) dyspnoea scale as a measure of disability in patients with chronic obstructive pulmonary diseaseThorax, 1999
- Corticosteroid effect on immunoglobulinsJournal of Allergy and Clinical Immunology, 1978